Subject characteristics
In the phase, I clinical trial, a total of 28 subjects received the vaccine and were grouped into nine groups. A total of 16 subjects (57.14%) were men, and 12 (42.83%) were women. The subjects of the study were in the age range of 18–61 years for men and 23–60 years for women. In the phase II clinical trial, a total of 145 subjects received the vaccine and were grouped into three groups (Demographic characteristics of phase II clinical trial subjects.